跳转至内容
Merck
CN
  • Injection of celiac disease patient sera or immunoglobulins to mice reproduces a condition mimicking early developing celiac disease.

Injection of celiac disease patient sera or immunoglobulins to mice reproduces a condition mimicking early developing celiac disease.

Journal of molecular medicine (Berlin, Germany) (2014-09-12)
Suvi Kalliokoski, Sergio Caja, Rafael Frias, Kaija Laurila, Outi Koskinen, Onni Niemelä, Markku Mäki, Katri Kaukinen, Ilma R Korponay-Szabó, Katri Lindfors
摘要

Typical features of celiac disease are small-bowel villus atrophy, crypt hyperplasia, and inflammation which develop gradually concomitant with ingestion of gluten. In addition, patients have anti-transglutaminase 2 (TG2) autoantibodies in their serum and tissues. The aim of this study was to establish whether celiac disease can be passively transferred to mice by serum or immunoglobulins. Serum aliquots or purified immunoglobulins (Ig) were intraperitoneally injected into Hsd:Athymic Nude-Foxn1nu mice for 8 or 27 days. As mice do not have proper IgA transport from peritoneum to blood, sera with a high content of IgG class anti-TG2 antibodies from untreated IgA-deficient celiac patients were used. Mouse sera were tested for celiac disease-specific autoantibodies, and several tissues were analyzed for autoantibody deposits targeted to TG2. Morphological assessment was made of the murine small intestinal mucosa. Injection of celiac disease patient sera or total IgG led to a significant delay in weight gain and mild diarrhea in a subset of mice. The mice injected with celiac patient sera or IgG had significantly decreased villus height crypt depth (Vh/CrD) ratios and celiac disease-specific autoantibody deposits targeted to TG2 in several tissues, including the small intestine. None of these features were observed in control mice. We conclude that administration of IgA-deficient celiac disease patient serum or total IgG induces both deterioration of the intestinal mucosa and clinical features of celiac disease in mice. The experimentally induced condition in the mice injected with patient serum or IgG resembles early developing celiac disease in humans. Celiac disease patient sera or total IgG was injected into athymic mice. A significant delay in weight gain and mild diarrhea was observed. Mice evinced significantly decreased villus height crypt depth ratios. Celiac disease-specific autoantibody deposits were present in several tissues. The condition in mice resembles early stage celiac disease in humans.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
甘氨酸, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
甘氨酸, suitable for electrophoresis, ≥99%
Sigma-Aldrich
硫氰酸钾, ReagentPlus®, ≥99.0%
Sigma-Aldrich
甘氨酸, BioUltra, Molecular Biology, ≥99.0% (NT)
Sigma-Aldrich
甘氨酸, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
硫氰酸钾, ACS reagent, 99%
SAFC
甘氨酸
Supelco
甘氨酸, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甘氨酸, BioXtra, ≥99% (titration)
Sigma-Aldrich
甘氨酸, ACS reagent, ≥98.5%
Sigma-Aldrich
硫氰酸钾, BioXtra, ≥99.0%
Sigma-Aldrich
甘氨酸, 99%, FCC
Sigma-Aldrich
甘氨酸, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)
USP
甘氨酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
DL-丙氨酸, ≥99% (HPLC)
Sigma-Aldrich
甘氨酸, puriss. p.a., reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance)
Sigma-Aldrich
DL-丙氨酸, ≥99%, FCC, FG
Supelco
甘氨酸, analytical standard, for nitrogen determination according to Kjeldahl method
甘氨酸, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
硫氰酸钾 溶液, volumetric, 8 M KSCN
丙氨酸, European Pharmacopoeia (EP) Reference Standard
Supelco
甘氨酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
甘氨酸, tested according to Ph. Eur.
Sigma-Aldrich
甘氨酸, Vetec, reagent grade, 98%